The emerging role of the gut microbiota and its application in inflammatory bowel disease

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117302 - 117302

Published: Aug. 19, 2024

Inflammatory bowel disease (IBD), including Crohn's and ulcerative colitis, is a complex disorder with an unknown cause. However, the dysbiosis of gut microbiome has been found to play role in IBD etiology, exacerbated immune responses defective intestinal barrier integrity. The can also be potential biomarker for several diseases, IBD. Currently, conventional treatments targeting pro-inflammatory cytokines pathways IBD-associated do not yield effective results. Other therapies that directly target dysbiotic outcomes are emerging. We review health its as diagnostic, prognostic, therapeutic This explores emerging advancements microbiome-associated alterations IBD, such nanoparticle or encapsulation delivery, fecal microbiota transplantation, nutritional therapies, microbiome/probiotic engineering, phage therapy, mesenchymal stem cells (MSCs), proteins, herbal formulas.

Language: Английский

---

Gut microbiota and blood biomarkers in IBD-Related arthritis: insights from mendelian randomization

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 2, 2025

With the ongoing rise in incidence of inflammatory bowel disease (IBD), its extraintestinal manifestations have garnered significant attention. IBD-related arthritis is notable for insidious onset and unpredictability, presenting considerable challenges clinical diagnosis management. Factors such as gut microbiota, plasma proteins, biomarkers found blood urine may be closely associated with arthritis. However, mechanisms by which these factors influence this condition remain poorly understood require urgent investigation. We employed method linkage disequilibrium two-sample Mendelian randomization (MR) approach, utilizing single nucleotide polymorphisms (SNPs) identified from large-scale genome-wide association studies instrumental variables. In scientifically rigorous manner, we explored potential causal relationship between relation to resulting (IBD). This aids elucidating roles development following IBD, while minimizing confounding reverse causality commonly encountered observational studies. To further verify strengthen our findings, conducted subsequent sensitivity analyses. These analyses will evaluate strength SNPs studied biomarkers, well post-IBD arthritis, accounting variations SNP distribution among populations other genetic influencing factors. Through analytical steps, objective enhance robustness credibility research findings provide more reliable scientific evidence regarding pathogenesis MR analysis provides genetically predicted risk investigates characteristics associations specific Among pterin-4-alpha-carbinolamine dehydratase, aldo-keto reductase family 1 member C4, cathepsin L2, angiostatin, hepatocyte growth factor-like protein, hepatitis A virus cellular receptor 2, protein O-linked mannose beta-1,4-N-acetylglucosaminyltransferase epididymal-specific alpha-mannosidase, platelet-derived factor receptor-like are Crohn's disease-related contrast, agrin, methylenetetrahydrofolate synthetase domain-containing neurotrophin-3 (NT-3) receptor, neuropilin-1 ulcerative colitis-related Furthermore, bacterial pathway abundance, adenosylcobalamin, N-acetylglucosamine, N-acetylmannosamine, N-acetylneuraminic acid degradation, glycolysis metabolism degradation pathways, Meanwhile, abundance (pentose phosphate pathway) microbiota (Bacteroidetes, Bacteroidia, Bacteroidales, Porphyromonadaceae, Faecalibacterium, Eubacterium eligens) linked Notably, did not identify any connections factors, Lastly, study, insufficient number available precluded detection a relationship. study employs elucidate relationships occurrence progression offers novel perspective deeper understanding highlights future directions treatment strategies condition.

Language: Английский

---

3'-Sialyllactose and B. infantis synergistically alleviate gut inflammation and barrier dysfunction by enriching cross-feeding bacteria for short-chain fatty acid biosynthesis

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 7, 2025

Ulcerative colitis (UC) poses significant threats to human health and quality of life worldwide, as it is a chronic inflammatory bowel disease. 3'-sialyllactose (3'-SL) key functional component milk oligosaccharides. This study systematically evaluates the prebiotic effects 3'-SL its therapeutic potential in combination with Bifidobacterium infantis (B. infantis) for UC. The findings reveal that B. synergistically mitigate intestinal inflammation barrier dysfunction by promoting production short-chain fatty acids (SCFAs) through cross-feeding mechanisms among gut microbiota. Individually, 3'-SL, infantis, synbiotic treatment all effectively alleviated UC symptoms, including reduced weight loss, improved disease activity scores, prevention colon shortening. Histopathological immunofluorescence analyses further demonstrated significantly ameliorated colonic injury, enhanced function, restored goblet cell counts, increased glycoprotein content crypt cells, upregulated expression tight junction proteins (ZO-1, occludin, claudin-1). Notably, outperformed individual components better restoring microbiota balance, elevating SCFA levels, modulating serum cytokine profiles, thereby reducing inflammation. These provide mechanistic insights into protective underscore other disorders.

Language: Английский

---

Fecal Mycobiota in Patients with Inflammatory Bowel Diseases and Extraintestinal Manifestations

Gut Microbes Reports, Journal Year: 2024, Volume and Issue: 1(1), P. 1 - 12

Published: Sept. 20, 2024

Language: Английский

---